In this episode of Top Biotechs at ASCO, Ying Huang, CEO of Legend Biotech, a leader in cell therapy innovation. Ying shares exciting five-year data for Carvykti (cilta-cel), Legend’s CAR-T therapy for relapsed/refractory multiple myeloma, presented at ASCO 2025.
Legend’s latest results from the CAR-2.1 study show unprecedented outcomes:
- One-third of patients remain progression-free five years after a single infusion.
- Median overall survival extended to 60 months.
- Deep responses with MRD negativity in many patients.